Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in Real-World Clinical Practice

Area of Science:

• Oncology
• Genomics
• Precision Medicine

Background:

• Next-generation sequencing based comprehensive genomic profiling (CGP) is increasingly adopted in cancer care.
• While CGP can identify actionable genomic alterations, its real-world clinical utility across diverse cancer types in community settings is not well-established.

Purpose of the Study:

• To evaluate the clinical impact of routine comprehensive genomic profiling (CGP) in a community-based cancer center.
• To assess the frequency of actionable genomic alterations and their correlation with treatment changes and clinical benefit across various cancer types.

Main Methods:

• A retrospective study analyzed data from 333 patients who underwent CGP between January 2013 and June 2017.
• CGP was performed in addition to standard molecular testing for specific cancer types like non-small cell lung cancer (NSCLC) and colorectal cancer.
• Genomic alteration data was cross-referenced with treatment recommendations and clinical outcomes.

Main Results:

• 95% of patients had at least one actionable genomic alteration identified by CGP.
• Actionable alterations led to available Food and Drug Administration (FDA)-approved therapies in 23.2%, off-label therapies in 61.3%, and clinical trial eligibility in 77.9%.
• Treatment changes occurred in 10% of patients, primarily in NSCLC, with 5% experiencing documented clinical benefit from targeted therapy.

Conclusions:

• Routine CGP in community oncology practice identifies potentially actionable genomic alterations in a majority of patients.
• The overall clinical impact of CGP is modest, with benefits most pronounced in the non-small cell lung cancer (NSCLC) subset.